University of Washington Arboviral Research Network (UWARN)

摘要：华盛顿大学虫媒病毒研究网络（UWARN） 华盛顿大学虫媒病毒研究网络（UWARN）将致力于解决新兴和重新出现的虫媒病毒问题 通过对包括当前高负荷病原体在内的虫媒病毒进行研究来预防传染病 登革热、基孔肯雅热和寨卡病毒。虫媒病毒还包括新出现和重新出现的病毒，例如 马亚罗病、乌纳病、乌苏图病、日本脑炎、黄热病、克里米亚-刚果出血热和奥罗普切病 病毒。 UWARN 将利用威斯康辛大学元中心进行流行病防范和强有力的研究 巴西、塞内加尔、南非、巴基斯坦和台湾的实验室合作伙伴以及威斯康星大学 全球卫生在能力建设方面的全球影响力。 UWARN 国际合作伙伴有 以机构和人口为基础的队列到位，以开展计划的研究和监测新的 病毒的出现。拟议的 UWARN 研究将创造新的人类病毒中和单克隆抗体 可用作治疗或诊断的抗体（Hu-nMab）。 UWARN研究也将创造新的 诊断，由蛋白质设计研究所从头开始创建，作为人造蛋白质，当 体液中存在病毒抗体。最后，UWARN 研究将了解如何 病毒操纵人类先天免疫系统，这些信息将用于设计生物标志物 预测严重疾病并建议针对宿主的治疗，这些治疗可能会在治疗后带来更好的结果 虫媒病毒感染。所提出的技术是通用的，可以快速适应任何未来的新兴技术 虫媒病毒威胁。 UWARN 的合作者涵盖病毒学、细菌学、真菌学和寄生虫感染领域，因此 UWARN 可以应对各种新出现的传染病威胁。 UWARN国际实验室有 先进的功能，包括配备发电机备用 -80C 冰箱的生物样本库、下一代 测序 (NGS) 功能、荧光细胞分选和 BSL-3 防护设施。 UWARN 队列有 生物库样本取自急性发热性疾病期间的个体，其中含有已知和未知的虫媒病毒 疾病和合作伙伴站点已准备好前瞻性地收集人口和设施样本。 UWARN 实验室将使用宏基因组 NGS 来检测附属队列中新病毒的出现。优警告合作伙伴 与昆虫学家和兽医合作，对节肢动物媒介和动物宿主进行采样 需要。其他创新能力包括巴西 UWARN 合作伙伴配备 NGS 的移动货车 能够在 18 小时内进行实时现场病毒测序和采样以进行病毒鉴定。一秒钟 塞内加尔的合作伙伴 IRESSEF 计划在塞内加尔建立一个类似的移动车辆，用于病毒采样和测序 塞内加尔和巴西集团将与 IRESSEF 在技术转让和最佳实践方面进行合作。警告 合作伙伴将作为其他新发传染病研究中心 (EIDRC) 的资源，提供 单克隆抗体、蛋白质设计和宿主定向疗法方面的专业知识。

Abstract: University of Washington Arboviral Research Network (UWARN) The University of Washington Arboviral Research Network (UWARN) will address emerging and re-emerging infectious diseases by carrying out research on arboviruses that include current high burden pathogens including dengue, chikungunya, and Zika viruses. Arboviruses also include emerging and re-emerging viruses such as Mayaro, Una, Usutu, Japanese encephalitis, yellow fever, Crimean-Congo hemorrhagic fever, and Oropouche viruses. UWARN will leverage the UW Metacenter for Pandemic Disease Preparedness and strong research laboratory partners in Brazil, Senegal, South Africa, Pakistan and Taiwan as well as the UW Department of Global Health global reach in capacity building. The UWARN international Collaborating Partners have institution-based and population-based cohorts in place to carry out the planned research and monitor for new virus emergence. The proposed UWARN research will create new human viral-neutralizing monoclonal antibodies (Hu-nMabs) that can be used as therapeutics or diagnostics. UWARN research will also create new diagnostics, created ab initio by the Institute for Protein Design, as artificial proteins that release light when antibodies to virus are present in body fluids. Finally, UWARN research will generate an understanding of how viruses manipulate the human innate immune system, and this information will be used to design biomarkers to predict severe disease as well as to suggest host-directed therapies that could lead to better outcomes after arboviral infection. The proposed technologies are generic and could be rapidly adapted to any future emerging arbovirus threat. UWARN collaborators span virology, bacteriology, mycology, and parasitic infections, such that UWARN can respond to diverse emerging infectious diseases threats. UWARN international laboratories have advanced capabilities including biorepositories with generator-power backed-up -80C freezers, next-generation sequencing (NGS) capabilities, fluorescence cell sorting, and BSL-3 containment facilities. UWARN cohorts have biobanked samples taken from individuals during acute febrile illnesses, with known and unknown arboviral diseases, and partnership sites are poised for prospective collection of population and facility–based samples. UWARN labs will use metagenomic NGS to detect novel viral emergence in affiliated cohorts. UWARN Partners have collaborating entomologists and veterinarians to sample arthropod vectors and animal reservoirs as needed. Additional innovative capacity included the Brazil UWARN partner’s mobile van with on board NGS capability for real-time, on-site viral sequencing and sampling to viral identification in less than 18 hrs. A second partner, IRESSEF in Senegal, plans to set up a similar mobile vehicle for viral sampling and sequencing in Senegal and the Brazil group will collaborate with IRESSEF on technology transfer and best practices. UWARN partners will serve as a resource to other Emerging Infectious Diseases Research Centers (EIDRC) providing expertise in monoclonal antibodies, protein design, and host directed therapies.